Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1593-1596

  Spanoudakis, E ^a   Margaritis, D ^a   Kotsianidis, I ^a   Georgiou, G ^b   Tripsianis, G ^a   Anastasiadis, A ^a   Karakolios, A ^a   Pantelidou, D ^a   Panayiotidis, P ^b   Bourikas, G ^a   Tsatalas, C ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Essential thrombocythemia; JAK2617V>F; LTBMC

Indexed keywords

JANUS KINASE;

AMINO ACID SUBSTITUTION; ARTICLE; BONE MARROW CULTURE; CONTROLLED STUDY; ERYTHROCYTE COUNT; GRANULOCYTE; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AMINO ACID SUBSTITUTION; CELLS, CULTURED; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; POINT MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 44749094650     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.013     Document Type: Article

References (10)

1. John M., and Goldman D.M. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352 (2005) 17
2. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 4 (2007) 1092-1097
3. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 6 (2005) 2162-2169
4. Campbell P.J., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The Lancet 366 (2005) 1945-1954
5. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haem 131 (2005) 208-213
6. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109 6 (2007) 2310-2313
7. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J.P., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108 10 (2006) 3548-3555
8. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
9. Delhommeau F., Dupont S., Tonetti C., Massé A., Godin I., Le Couedic J.-P., et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109 1 (2007) 375-379
10. Jantunen R., Juvonen E., Aimolahti A., and Ruutu T. Long-term bone marrow cultures in polycythemia vera and essential thrombocythemia. Acta Haematol 96 (1996) 227-231